Have We Found the Panacea to Covid-19 with Remdesivir, An Old but Newly Packaged Drug?

Investigators provided open-label remdesivir on a compassionate-use basis to patients hospitalised with severe COVID-19, an illness caused by infection with SARSCoV-2. Severity was defi ned as an oxygen saturation of 94% or less while patients were breathing ambient air or receiving oxygen support. Patients with contraindications for remdesivir, including creatinine clearance below 30 ml/min and elevated liver enzymes beyond fi ve times upper limit of normal, were excluded. Patients received a 10-day course of intravenous remdesivir, starting with loading dose of 200 mg administered intravenously on day one, followed by 100 mg daily for the remaining nine days.